Next Article in Journal
The Effect of α-Monolaurin and Butyrate Supplementation on Broiler Performance and Gut Health in the Absence and Presence of the Antibiotic Growth Promoter Zinc Bacitracin
Previous Article in Journal
Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance
Previous Article in Special Issue
The Influence of Cellulose-Type Formulants on Anti-Candida Activity of the Tyrocidines
Review

The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent

Department of Health Sciences, Carleton University, Ottawa, ON K1S 5B6, Canada
*
Author to whom correspondence should be addressed.
Academic Editors: Giovanna Batoni, Giuseppantonio Maisetta and Semih Esin
Antibiotics 2021, 10(6), 650; https://doi.org/10.3390/antibiotics10060650
Received: 24 March 2021 / Revised: 20 May 2021 / Accepted: 25 May 2021 / Published: 29 May 2021
(This article belongs to the Special Issue Therapeutic Use of Antimicrobial Peptides: Joys and Sorrows)
The rise in antimicrobial resistant bacteria threatens the current methods utilized to treat bacterial infections. The development of novel therapeutic agents is crucial in avoiding a post-antibiotic era and the associated deaths from antibiotic resistant pathogens. The human antimicrobial peptide LL-37 has been considered as a potential alternative to conventional antibiotics as it displays broad spectrum antibacterial and anti-biofilm activities as well as immunomodulatory functions. While LL-37 has shown promising results, it has yet to receive regulatory approval as a peptide antibiotic. Despite the strong antimicrobial properties, LL-37 has several limitations including high cost, lower activity in physiological environments, susceptibility to proteolytic degradation, and high toxicity to human cells. This review will discuss the challenges associated with making LL-37 into a viable antibiotic treatment option, with a focus on antimicrobial resistance and cross-resistance as well as adaptive responses to sub-inhibitory concentrations of the peptide. The possible methods to overcome these challenges, including immobilization techniques, LL-37 delivery systems, the development of LL-37 derivatives, and synergistic combinations will also be considered. Herein, we describe how combination therapy and structural modifications to the sequence, helicity, hydrophobicity, charge, and configuration of LL-37 could optimize the antimicrobial and anti-biofilm activities of LL-37 for future clinical use. View Full-Text
Keywords: LL-37; antimicrobial peptide; anti-biofilm peptide; antimicrobial resistance; LL-37 derivatives LL-37; antimicrobial peptide; anti-biofilm peptide; antimicrobial resistance; LL-37 derivatives
Show Figures

Figure 1

MDPI and ACS Style

Ridyard, K.E.; Overhage, J. The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. Antibiotics 2021, 10, 650. https://doi.org/10.3390/antibiotics10060650

AMA Style

Ridyard KE, Overhage J. The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. Antibiotics. 2021; 10(6):650. https://doi.org/10.3390/antibiotics10060650

Chicago/Turabian Style

Ridyard, Kylen E., and Joerg Overhage. 2021. "The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent" Antibiotics 10, no. 6: 650. https://doi.org/10.3390/antibiotics10060650

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop